K2
11 known investors
Find your way into K2
K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials. Its pipeline focuses on first- and best-in-class cell therapies for solid tumors, including a PRAME-targeting therapy for cutaneous melanoma and synovial sarcoma.
Investors · 11
MPM BioImpactBoston · $1M – $15M
Alpine Space VenturesreportedMunich · $11M – $22M
Altimeter Capitalreported · 2 sourcesMenlo Park · $1M – $25M
CapitalGreported · 2 sourcesSan Francisco · $50M – $100M
ICONIQreported · 2 sourcesSan Francisco
Kleiner Perkinsreported · 2 sourcesMenlo Park · $500K – $15M
Lightspeed Venture Partnersreported · 2 sourcesMenlo Park · $1.7M – $87M
Redpoint VenturesreportedWoodside · $100K – $10M
Sands Capital Venturesreported · 2 sourcesArlington · $10M – $30M
Spark Capitalreported · 2 sourcesSan Francisco · $500K – $25M
T. Rowe Pricereported · 2 sourcesBaltimore
In the news
K2 Space Raises $500M Series D to Scale High-Power Satelliteslatimes.com · Aug 2026Frequently asked questions
- What does K2 do?
- K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials. Its pipeline focuses on first- and best-in-class cell therapies for solid tumors, including a PRAME-targeting therapy for cutaneous melanoma and synovial sarcoma.
- Who are K2's investors?
- K2's investors include MPM BioImpact, Alpine Space Ventures, Altimeter Capital, CapitalG, ICONIQ, Kleiner Perkins, Lightspeed Venture Partners, Redpoint Ventures and 3 more.